Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer (vol 24, pg 638, 2018)

被引：0
|
作者：
Robichaux, Jacqulyne P.
Elamin, Yasir Y.
Tan, Zhi
Carter, Brett W.
Zhang, Shuxing
Liu, Shengwu
Li, Shuai
Chen, Ting
Poteete, Alissa
Estrada-Bernal, Adriana
Le, Anh T.
Truini, Anna
Nilsson, Monique B.
Sun, Huiying
Roarty, Emily
Goldberg, Sarah B.
Brahmer, Julie R.
Altan, Mehmet
Lu, Charles
Papadimitrakopoulou, Vassiliki
Politi, Katerina
Doebele, Robert C.
Wong, Kwok-Kin
Heymach, John V.
机构：
[1] University of Texas MD Anderson Cancer Center,Department of Thoracic Head and Neck Medical Oncology
[2] University of Texas MD Anderson Cancer Center,Department of Experimental Therapeutics
[3] University of Texas MD Anderson Cancer Center,Department of Diagnostic Radiology
[4] Dana-Farber Cancer Institute,Lowe Center for Thoracic Oncology
[5] University of Colorado Cancer Center,Yale Cancer Center
[6] Yale University School of Medicine,Department of Medicine
[7] Yale University School of Medicine,Sidney Kimmel Comprehensive Cancer Center
[8] Johns Hopkins University,Department of Pathology
[9] Yale University School of Medicine,Laura & Isaac Perlmutter Cancer Center
[10] New York University Langone Medical Center,undefined
来源：
NATURE MEDICINE | 2024年
关键词：
D O I：
10.1038/s41591-024-03178-1
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：2694 / 2695
页数：2
相关论文
共 50 条
  • [1] Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer
    Robichaux, Jacqulyne P.
    Elamin, Yasir Y.
    Tan, Zhi
    Carter, Brett W.
    Zhang, Shuxing
    Liu, Shengwu
    Li, Shuai
    Chen, Ting
    Poteete, Alissa
    Estrada-Bernal, Adriana
    Le, Anh T.
    Truini, Anna
    Nilsson, Monique B.
    Sun, Huiying
    Roarty, Emily
    Goldberg, Sarah B.
    Brahmer, Julie R.
    Altan, Mehmet
    Lu, Charles
    Papadimitrakopoulou, Vassiliki
    Politi, Katerina
    Doebele, Robert C.
    Wong, Kwok-Kin
    Heymach, John V.
    NATURE MEDICINE, 2018, 24 (05) : 638 - +
  • [2] An Exon 20-Selective Kinase Inhibitor in Non-Small Cell Lung Cancer
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (01) : 12 - 12
  • [3] Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
    Brazel, Danielle
    Kroening, Gianna
    Nagasaka, Misako
    BIODRUGS, 2022, 36 (06) : 717 - 729
  • [4] Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options
    Danielle Brazel
    Gianna Kroening
    Misako Nagasaka
    BioDrugs, 2022, 36 : 717 - 729
  • [5] Clinical Outcome of Non-Small Cell Lung Cancer with EGFR/HER2 Exon 20 Insertions Identified in the LC-SCRUM-Japan
    Udagawa, H.
    Matsumoto, S.
    Ohe, Y.
    Satouchi, M.
    Furuya, N.
    Kim, Y. H.
    Seto, T.
    Soejima, K.
    Hayakawa, D.
    Kato, T.
    Miyamoto, S.
    Ohashi, K.
    Saeki, S.
    Ohta, H.
    Fujimoto, D.
    Sekine, A.
    Yoh, K.
    Goto, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S224 - S224
  • [6] A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC)
    Heymach, J.
    Negrao, M.
    Robichaux, J.
    Carter, B.
    Patel, A.
    Altan, M.
    Gibbons, D.
    Fossella, F.
    Simon, G.
    Lam, V.
    Blumenschein, G.
    Tsao, A.
    Kurie, J.
    Mott, F.
    Jenkins, D.
    Mack, D.
    Feng, L.
    Roeck, B.
    Yang, Z.
    Papadimitrakopoulou, V.
    Elamin, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S323 - S324
  • [7] A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer
    Son, Jieun
    Jang, Jaebong
    Beyett, Tyler S.
    Eum, Yoonji
    Haikala, Heidi M.
    Verano, Alyssa
    Lin, Mika
    Hatcher, John M.
    Kwiatkowski, Nicholas P.
    Eser, Pinar O.
    Poitras, Michael J.
    Wang, Stephen
    Xu, Man
    Gokhale, Prafulla C.
    Cameron, Michael D.
    Eck, Michael J.
    Gray, Nathanael S.
    Janne, Pasi A.
    CANCER RESEARCH, 2022, 82 (08) : 1633 - 1645
  • [8] Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
    Wang, Mengzhao
    Yang, James Chih-Hsin
    Mitchell, Paul L.
    Fang, Jian
    Camidge, D. Ross
    Nian, Weiqi
    Chiu, Chao-Hua
    Zhou, Jianying
    Zhao, Yanqiu
    Su, Wu-Chou
    Yang, Tsung-Ying
    Zhu, Viola W.
    Millward, Michael
    Fan, Yun
    Huang, Wen-Tsung
    Cheng, Ying
    Jiang, Liyan
    Brungs, Daniel
    Bazhenova, Lyudmila
    Lee, Chee Khoon
    Gao, Bo
    Xu, Yan
    Hsu, Wei-Hsun
    Zheng, Li
    Janne, Pasi A.
    CANCER DISCOVERY, 2022, 12 (07) : 1676 - 1689
  • [9] A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome
    Cognigni, Valeria
    Capelletto, Enrica
    Bordi, Paola
    Pavese, Valeria
    Carfi, Federica Maria
    Gelsomino, Francesco
    De Giglio, Andrea
    Chiari, Rita
    Minari, Roberta
    Ambrosini, Enrico
    Percesepe, Antonio
    Giachino, Daniela
    Bironzo, Paolo
    Tiseo, Marcello
    TUMORI JOURNAL, 2024,
  • [10] Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis
    Zhang, Mai
    Huang, Qian
    Yu, Min
    Xue, Jianxin
    Huang, Meijuan
    Lu, You
    Zhang, Yan
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (04) : 797 - 807
12345